- Home
- About
- Find staff
- Joachim Siaw
Joachim Siaw
Postdoctor
Department of Medical Biochemistry and Cell biology-
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer
CLEAN
Jonatan L. Gabre, Peter Merseburger, Arne Claeys, Joachim T. Siaw, Sarah Lee Bekaert, Frank Speleman, Bengt Hallberg, Ruth H. Palmer, Jimmy Van den Eynden
NAR Cancer - 2024 -
A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal
tissues
Tom Luijts, Kerryn Elliott, Joachim T. Siaw, J. Van de Velde, E. Beyls, A. Claeys, T. Lammens, Erik Larsson, W. Willaert, A. Vral, J. Van den Eynden
Scientific Reports - 2022 -
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase
Activation
D. Treis, Ganesh Umapathy, Susanne Fransson, Jikui Guan, Patricia Mendoza-García, Joachim T. Siaw, S. Wessman, L. G. Murkes, J. J. E. Stenman, Anna Djos, L. H. M. Elfman, J. I. Johnsen, Bengt Hallberg, Ruth H. Palmer, Tommy Martinsson, P. Kogner
JCO Precision Oncology - 2022 -
ATR inhibition enables complete tumour regression in ALK-driven NB mouse
models
Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim T. Siaw, A. Claeys, Jonatan L. Gabre, J. van den Eynden, Bengt Hallberg, Ruth H. Palmer
Nature Communications - 2021 -
BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma
Cells
Ezgi Uçkun, Joachim T. Siaw, Jikui Guan, Vimala Anthonydhason, Johannes Fuchs, Georg Wolfstetter, Bengt Hallberg, Ruth H. Palmer
Journal of Molecular Biology - 2021 -
Loss of RET Promotes Mesenchymal Identity in Neuroblastoma
Cells
Joachim T. Siaw, Jonatan L. Gabre, Ezgi Uçkun, M. Vigny, W. C. Zhang, J. Van den Eynden, Bengt Hallberg, Ruth H. Palmer, Jikui Guan
Cancers - 2021 -
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in
Neuroblastoma
Joachim T. Siaw, Niloufar Javanmardi, Jimmy Van den Eynden, Dan E. Lind, Susanne Fransson, Angela Martinez-Monleon, Anna Djos, Rose-Marie Sjöberg, Malin Östensson, H. Caren, G. Troen, K. Beiske, A. P. Berbegall, R. Noguera, Wei-Yun Lai, P. Kogner, Ruth H. Palmer, Bengt Hallberg, Tommy Martinsson
Cell Reports - 2020 -
Anaplastic lymphoma kinase activity, a therapeutic target, suppresses neuroblastoma cell
differentiation
Joachim T. Siaw
2020 -
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor
ceritinib.
Jikui Guan, Susanne Fransson, Joachim T. Siaw, Diana Treis, Jimmy Van den Eynden, Damini Chand, Ganesh Umapathy, Kristina Ruuth, Alia Shamikh, Hans Jacobsson, Lena Gordon, Par-Johan Svensson, Magnus Hansson, Tommy Martinsson, Per Kogner, Ruth H. Palmer, Bengt Hallberg
Cold Spring Harbor molecular case studies - 2018 -
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not
ligand-independent.
Jikui Guan, Georg Wolfstetter, Joachim T. Siaw, Damini Chand, Fredrik Hugosson, Ruth H. Palmer, Bengt Hallberg
Oncotarget - 2017 -
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and
mice
Joachim T. Siaw, Haiying Wang, Kathrin Pfeifer, V. M. Rivera, Jikui Guan, Ruth H. Palmer, Bengt Hallberg
Oncotarget - 2016